Dosing and uses of Cantil (mepenzolate)
Adult dosage forms and strengths
tablet
- 25mg
Peptic Ulcer
25-50 mg PO q6hr (with meals & HS), titrate as needed
Elderly: Start at lower end of dose
Pediatric dosage forms and strengths
Safety & efficacy not established
Geriatric dosage forms and strengths
Peptic ulcer
25-50 mg PO q6hr (with meals & HS), titrate as needed
Elderly: Start at lower end of dose
Cantil (mepenzolate) adverse (side) effects
Frequency not defined
Dizziness
Confusion
Headache
Insomnia
Nervousness
Weakness
Drowsiness
Tachycardia
Palpitations
Vomiting
Nausea
Taste loss
Dry mouth
Constipation
Bloated feeling
Urinary retention
Urinary hesitancy
Increased IOp
Cycloplegia
Mydriasis
Blurred vision
Anaphylaxis
Urticaria
Decreased sweating
Inhibition of lactation
Impotence
Warnings
Contraindications
Hypersensitivity to mepenzolate or related compounds
Closed-angle glaucoma, myasthenia gravis, hemorrhage with cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated patient, obstructive uropathy, toxic megacolon, GI obstruction, tachycardia secondary to cardiac insufficiency or thyrotoxicosis
Cautions
Renal/hepatic impairment, BPH, CHF, CAD, HTN, COPD, hiatal hernia, reflux esophagitis, mitral stenosis, brain damage or spastic paralysis in children, salivary secretion disorder, Down syndrome, autonomic neuropathy, hyperthyroidism, tachyarrythmia, toxin-mediated diarrhea
Elderly (see Beers Criteria)
Risk of heat prostration in high environmental temperature
May affect alertness/ability to perform hazardous tasks
Pregnancy and lactation
Pregnancy category: B
Lactation: unlikely to be excreted in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Cantil (mepenzolate)
Mechanism of action
Postganglionic parasympathetic inhibitor. Inhibits gastric acid and pepsin secretion and inhibits spontaneous contractions of the colon
Pharmacokinetics
Absorption: Limited
Excretion: Urine (3-33%) & feces
